{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T22:50:55Z","timestamp":1788648655225,"version":"build-2803163510"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>The purpose of this study is to examine the prognostic significance of the amalgamated indicators, reticulocyte percentage (RET%), lactate dehydrogenase (LDH), and \u03b3-Glutamyltransferase (\u03b3-GT), in neonatal ABO hemolytic disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 137 hospitalized children with pathological jaundice were included. Based on their medical conditions, they were categorized into two groups, hemolytic (67 cases) and non-hemolytic (70 cases). Pearson linear correlation and binary logistic multivariate analysis were used to analyze LDH, \u03b3-GT, RET% and hemolysis. Furthermore, the predictive value of the combined predictors of RET%, LDH, and \u03b3-GT on ABO neonatal hemolytic disease was evaluated using the ROC curve analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The laboratory indexes of the two groups were subject to analysis using binary logistic regression to identify suspicious influencing factors. The study revealed that RET%, LDH, and \u03b3-GT were independent risk factors for hemolysis. Pearson linear correlation analysis indicated a positive correlation between LDH and \u03b3-GT with RET% (<jats:italic>r<\/jats:italic>\u2009=\u20090.529, <jats:italic>P<\/jats:italic>\u2009&amp;lt;\u20090.01; <jats:italic>r<\/jats:italic>\u2009=\u20090.526, <jats:italic>P<\/jats:italic>\u2009=\u2009&amp;lt;0.01, respectively). Furthermore, the predictive value of each combined predictor was obtained using the ROC curve, and it was observed that combined predictor L (RET%\u2009+\u2009LDH\u2009+\u2009\u03b3-GT)&amp;gt;L1 (RET%\u2009+\u2009LDH)&amp;gt;L2 (RET%\u2009+\u2009\u03b3-GT).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Combined predictor L (RET%\u2009+\u2009LDH\u2009+\u2009\u03b3-GT)demonstrate its optimal diagnostic efficacy, offering a novel approach towards diagnosing early-onset ABO hemolytic disease of the newborn.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2023.1265739","type":"journal-article","created":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T17:33:12Z","timestamp":1701451992000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Clinical value of combined predictors of RET%, \u03b3-GT, LDH in the ABO neonatal hemolytic disease"],"prefix":"10.3389","volume":"11","author":[{"given":"Xiaoxiao","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingchao","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,12,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.cll.2020.10.009","article-title":"Hemolytic disease of the fetus and newborn: historical and current state","volume":"41","author":"Jackson","year":"2021","journal-title":"Clin Lab Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1097\/MPH.0000000000001248","article-title":"Severe ABO hemolytic disease of the newborn requiring exchange transfusion","volume":"41","author":"Metcalf","year":"2019","journal-title":"J Pediatr Hematol Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1182\/blood-2018-08-833962","article-title":"Transfusion-related red blood cell alloantibodies: induction and consequences","volume":"133","author":"Tormey","year":"2019","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1097\/MPH.0000000000001248","article-title":"Severe ABO hemolytic disease of the newborn requiring exchange transfusion","volume":"41","author":"Metcalf","year":"2019","journal-title":"J Pediatr Hemato Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"14385","DOI":"10.1038\/s41598-022-17933-2","article-title":"Assessment, management, and incidence of neonatal jaundice in healthy neonates cared for in primary care: a prospective cohort study","volume":"12","author":"van der Geest","year":"2022","journal-title":"Sci Rep"},{"key":"B6","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/bjh.18170","article-title":"International guidelines regarding the role of IVIG in the management of Rh- and ABO-mediated haemolytic disease of the newborn","volume":"198","author":"Lieberman","year":"2022","journal-title":"Br J Haematol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/s41372-022-01556-6","article-title":"ABO Hemolytic disease of the newborn: a need for clarity and consistency in diagnosis","volume":"43","author":"Watchko","year":"2023","journal-title":"J Perinatol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1542\/peds.110.1.127","article-title":"Isoimmunization is unlikely to be the cause of hemolysis in ABO-incompatible but direct antiglobulin test-negative neonates","volume":"110","author":"Herschel","year":"2002","journal-title":"Pediatrics"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e24034","DOI":"10.1002\/jcla.24034","article-title":"The diagnostic protocol for hereditary spherocytosis-2021 update","volume":"35","author":"Wu","year":"2021","journal-title":"J Clin Lab Anal"},{"key":"B10","doi-asserted-by":"publisher","first-page":"864609","DOI":"10.3389\/fped.2022.864609","article-title":"Intravenous immunoglobulin use in hemolytic disease due to ABO incompatibility to prevent exchange transfusion","volume":"10","author":"Okulu","year":"2022","journal-title":"Front Pediatr"},{"key":"B11","doi-asserted-by":"publisher","first-page":"119.e1","DOI":"10.1016\/j.ajog.2020.01.028","article-title":"Suppression of compensatory erythropoiesis in hemolytic disease of the fetus and newborn due to intrauterine transfusions","volume":"223","author":"Ree","year":"2020","journal-title":"Am J Obstet Gynecol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1002\/ajh.25960","article-title":"C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab","volume":"95","author":"de Castro","year":"2020","journal-title":"Am J Hematol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/trf.16745","article-title":"Complement-mediated hemolysis persists year round in patients with cold agglutinin disease","volume":"62","author":"R\u00f6th","year":"2022","journal-title":"Transfusion"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.18553\/jmcp.2022.28.12.1419","article-title":"An observational analysis of disease burden in patients with cold agglutinin disease: results from a large US electronic health record database","volume":"28","author":"Pham","year":"2022","journal-title":"J Manag Care Spec Pharm"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.kint.2020.01.035","article-title":"The long-acting C5 inhibitor, ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome na\u00efve to complement inhibitor treatment","volume":"7","author":"Rondeau","year":"2020","journal-title":"Kidney Int"},{"key":"B16","doi-asserted-by":"publisher","first-page":"3458","DOI":"10.4103\/jfmpc.jfmpc_570_20","article-title":"Serum GGT and serum ferritin as early markers for metabolic syndrome","volume":"9","author":"Mohapatra","year":"2020","journal-title":"J Family Med Prim Care"},{"key":"B17","doi-asserted-by":"publisher","first-page":"643","DOI":"10.7705\/biomedica.5930","article-title":"Hemolytic disease in fetuses and newborns due to antibodies against the M-antigen","volume":"41","author":"P\u00e1ez","year":"2021","journal-title":"Biomedica"},{"key":"B18","doi-asserted-by":"publisher","first-page":"699","DOI":"10.12968\/hmed.2017.78.12.699","article-title":"Neonatal jaundice: aetiology, diagnosis and treatment","volume":"78","author":"Mitra","year":"2017","journal-title":"Br J Hosp Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1159\/000518782","article-title":"Laboratory monitoring of mother, fetus, and newborn in hemolytic disease of fetus and newborn","volume":"48","author":"Dziegiel","year":"2021","journal-title":"Transfus Med Hemother"},{"key":"B20","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s41372-018-0048-4","article-title":"ABO hemolytic disease of the fetus and newborn: thirteen years of data after implementing a universal bilirubin screening and management program","volume":"38","author":"Christensen","year":"2018","journal-title":"J Perinatol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e2022058865","DOI":"10.1542\/peds.2022-058865","article-title":"Technical report: diagnosis and management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation","volume":"150","author":"Slaughter","year":"2022","journal-title":"Pediatrics"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e323","DOI":"10.1016\/S2352-3026(21)00059-4","article-title":"Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Howard","year":"2021","journal-title":"Lancet Haematol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"883","DOI":"10.3109\/14767058.2014.938044","article-title":"Red blood cell distribution width: reference intervals for neonates","volume":"28","author":"Christensen","year":"2015","journal-title":"J Matern Fetal Neonatal Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.cca.2020.07.020","article-title":"Antioxidant nutrients and hemolysis in sickle cell disease","volume":"510","author":"Delesderrier","year":"2020","journal-title":"Clin Chim Acta"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1542\/peds.109.4.e53","article-title":"An early (sixth-hour) serum bilirubin measurement is useful in predicting the development of significant hyperbilirubinemia and severe ABO hemolytic disease in a selective high-risk population of newborns with ABO incompatibility","volume":"109","author":"Sarici","year":"2002","journal-title":"Pediatrics"},{"key":"B26","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1203\/00006450-199705000-00018","article-title":"Rhesus isoimmunization: increased hemolysis during early infancy","volume":"41","author":"Hayde","year":"1997","journal-title":"Pediatr Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.3390\/diagnostics11091549","article-title":"Severe presentation of congenital hemolytic anemias in the neonatal age: diagnostic and therapeutic issues","volume":"11","author":"Cortesi","year":"2021","journal-title":"Diagnostics"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2023.1265739\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T17:33:14Z","timestamp":1701451994000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2023.1265739\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,1]]},"references-count":27,"alternative-id":["10.3389\/fped.2023.1265739"],"URL":"https:\/\/doi.org\/10.3389\/fped.2023.1265739","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,1]]},"article-number":"1265739"}}